combine@alvar.ug

Access to affordable medicines and diagnostic tests for asthma and COPD in sub Saharan Africa: the Ugandan perspective

Access to affordable medicines and diagnostic tests for asthma and COPD in sub Saharan Africa: the Ugandan perspective

Show simple record

dc.contributor.author Kibirige, Davis
dc.contributor.author Kampiire, Leaticia
dc.contributor.author Atuhe, David
dc.contributor.author Mwebaze, Raymond
dc.contributor.author Katagira, Winceslaus
dc.contributor.author Muttamba, Winters
dc.contributor.author Nantanda, Rebecca
dc.contributor.author Worodria, William
dc.contributor.author Kirenga, Bruce
dc.date.accessioned 2021-01-01T17:39:07Z
dc.date.available 2021-01-01T17:39:07Z
dc.date.issued 2017
dc.identifier.issn 1471-2466
dc.identifier.uri http://combine.alvar.ug/handle/1/47387
dc.description.abstract Background: Equitable access to affordable medicines and diagnostic tests is an integral component of optimal clinical care of patients with asthma and chronic obstructive pulmonary disease (COPD). In Uganda, we lack contemporary data about the availability, cost and affordability of medicines and diagnostic tests essential in asthma and COPD management. Methods: Data on the availability, cost and affordability of 17 medicines and 2 diagnostic tests essential in asthma and COPD management were collected from 22 public hospitals, 23 private and 85 private pharmacies. The percentage of the available medicines and diagnostic tests, the median retail price of the lowest priced generic brand and affordability in terms of the number of days' wages it would cost the least paid public servant were analysed. Results: The availability of inhaled short acting beta agonists (SABA), oral leukotriene receptor antagonists (LTRA), inhaled LABA-ICS combinations and inhaled corticosteroids (ICS) in all the study sites was 75%, 60.8%, 46.9% and 45.4% respectively. None of the study sites had inhaled long acting anti muscarinic agents (LAMA) and inhaled long acting beta agonist (LABA)-LAMA combinations. Spirometry and peak flow-metry as diagnostic tests were available in 24.4% and 6.7% of the study sites respectively. Affordability ranged from 2.2 days' wages for inhaled salbutamol to 17.1 days' wages for formoterol/budesonide inhalers and 27.8 days' wages for spirometry. Conclusion: Medicines and diagnostic tests essential in asthma and COPD care are not widely available in Uganda and remain largely unaffordable. Strategies to improve access to affordable asthma and COPD medicines and diagnostic tests should be implemented in Uganda.
dc.description.sponsorship Uganda Diabetes Association, a diabetes professional association for diabetic patients and healthcare practitioners
dc.description.sponsorship NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL128156, R01HL128156, R01HL128156, R01HL128156] Funding Source: NIH RePORTER
dc.language English
dc.publisher BMC
dc.relation.ispartof Bmc Pulmonary Medicine
dc.subject Access
dc.subject Medicines
dc.subject Diagnostic tests
dc.subject Asthma
dc.subject COPD
dc.subject Sub Saharan Africa
dc.subject Uganda
dc.title Access to affordable medicines and diagnostic tests for asthma and COPD in sub Saharan Africa: the Ugandan perspective
dc.type Article
dc.identifier.isi 000417544700002
dc.identifier.doi 10.1186/s12890-017-0527-y
dc.identifier.pmid 29216852
dc.publisher.city LONDON
dc.publisher.address CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
dc.identifier.volume 17
dc.subject.wc Respiratory System
dc.subject.sc Respiratory System
dc.description.oa DOAJ Gold
dc.description.oa Green Published
dc.description.pages 10
dc.subject.kwp Middle-Income Countries
dc.subject.kwp Obstructive Pulmonary-Disease
dc.subject.kwp Availability
dc.subject.kwp Care
dc.identifier.articleno 179
dc.description.affiliation Uganda Martyrs Hosp Lubaga, Dept Med, POB 7146, Kampala, Uganda
dc.description.affiliation GlaxoSmithKline Pharmaceut Kenya Ltd, Med Unit, Kampala, Uganda
dc.description.affiliation IDRC, Kampala, Uganda
dc.description.affiliation Case Hosp Kampala, Dept Med, Kampala, Uganda
dc.description.affiliation St Francis Hosp Nsambya, Dept Med, Kampala, Uganda
dc.description.affiliation Makerere Univ, Coll Hlth Sci, Makerere Lung Inst, Kampala, Uganda
dc.description.affiliation Makerere Univ, Coll Hlth Sci, Dept Paediat & Child Hlth, Kampala, Uganda
dc.description.affiliation Mulago Natl Referral & Teaching Hosp, Div Pulmonol, Kampala, Uganda
dc.description.email kibirigedavis@gmail.com
dc.description.corr Kibirige, D (corresponding author), Uganda Martyrs Hosp Lubaga, Dept Med, POB 7146, Kampala, Uganda.; Kibirige, D (corresponding author), GlaxoSmithKline Pharmaceut Kenya Ltd, Med Unit, Kampala, Uganda.
dc.description.orcid Katagira, Winceslaus/0000-0003-4622-191X


This record appears in the collections of the following institution(s)

Show simple record

Search Entire Database


Browse

My Account